Study finds combination therapy using everolimus and a TEAD inhibitor reduces growth in sarcomas, indicating potential therapeutic benefits in PI3K-activated cancers.
Key Points
This research aims to explore the therapeutic targeting of PI3K, TAZ/YAP, and mTORC1 in sarcomas.
Investigated PI3K signaling activation due to PTEN loss in sarcomas
Examined the roles of TAZ and YAP in tumor growth using a sarcoma mouse model
Tested combination therapy with IK-930 and everolimus in sarcoma cell lines and in vivo models.
Combination therapy significantly reduced proliferation of PI3K-activated sarcoma cell lines
Synergistic effects observed in vivo, suggesting a new therapeutic strategy
Low doses of the combination treatment were effective, indicating potential clinical applicability.